JP2008541733A5 - - Google Patents

Download PDF

Info

Publication number
JP2008541733A5
JP2008541733A5 JP2008513805A JP2008513805A JP2008541733A5 JP 2008541733 A5 JP2008541733 A5 JP 2008541733A5 JP 2008513805 A JP2008513805 A JP 2008513805A JP 2008513805 A JP2008513805 A JP 2008513805A JP 2008541733 A5 JP2008541733 A5 JP 2008541733A5
Authority
JP
Japan
Prior art keywords
seq
antigen
antibody
amino acid
antibody fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008513805A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008541733A (ja
JP5027804B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/020688 external-priority patent/WO2006128103A2/en
Publication of JP2008541733A publication Critical patent/JP2008541733A/ja
Publication of JP2008541733A5 publication Critical patent/JP2008541733A5/ja
Application granted granted Critical
Publication of JP5027804B2 publication Critical patent/JP5027804B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008513805A 2005-05-26 2006-05-26 ヒト化抗cd40抗体およびその使用方法 Active JP5027804B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68485305P 2005-05-26 2005-05-26
US60/684,853 2005-05-26
PCT/US2006/020688 WO2006128103A2 (en) 2005-05-26 2006-05-26 Humanized anti-cd40 antibodies and their methods of use

Publications (3)

Publication Number Publication Date
JP2008541733A JP2008541733A (ja) 2008-11-27
JP2008541733A5 true JP2008541733A5 (OSRAM) 2009-07-16
JP5027804B2 JP5027804B2 (ja) 2012-09-19

Family

ID=37452957

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008513805A Active JP5027804B2 (ja) 2005-05-26 2006-05-26 ヒト化抗cd40抗体およびその使用方法

Country Status (19)

Country Link
US (4) US8303955B2 (OSRAM)
EP (1) EP1885399B1 (OSRAM)
JP (1) JP5027804B2 (OSRAM)
KR (1) KR100991010B1 (OSRAM)
CN (1) CN101237882B (OSRAM)
AT (1) ATE485057T1 (OSRAM)
AU (1) AU2006249305B2 (OSRAM)
BR (1) BRPI0610470A2 (OSRAM)
CA (1) CA2609269C (OSRAM)
CR (1) CR9562A (OSRAM)
DE (1) DE602006017690D1 (OSRAM)
EC (1) ECSP078026A (OSRAM)
ES (1) ES2354865T3 (OSRAM)
IL (1) IL187594A0 (OSRAM)
MA (1) MA29595B1 (OSRAM)
NO (1) NO341793B1 (OSRAM)
PL (1) PL1885399T3 (OSRAM)
RU (1) RU2407544C2 (OSRAM)
WO (1) WO2006128103A2 (OSRAM)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
ATE485057T1 (de) * 2005-05-26 2010-11-15 Seattle Genetics Inc Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung
MX2008007140A (es) * 2005-12-09 2009-03-04 Seattle Genetics Inc Metodos para utilizar agentes de union a cd40.
AU2008207898B2 (en) * 2007-01-23 2012-05-03 Xencor, Inc Optimized CD40 antibodies and methods of using the same
BRPI0820707A2 (pt) 2007-11-07 2015-06-16 Genentech Inc Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40
FR2942799B1 (fr) * 2009-03-06 2011-02-25 Lfb Biotechnologies Anticorps monoclonal anti-rhesus d
JP2012520073A (ja) 2009-03-10 2012-09-06 ベイラー リサーチ インスティテュート 抗原提示細胞ターゲティングワクチン
CN105837691B (zh) 2009-03-10 2021-06-29 贝勒研究院 靶向抗原呈递细胞的癌症疫苗
EP2406286B1 (en) 2009-03-10 2016-05-18 Baylor Research Institute Anti-cd40 antibodies and uses thereof
US9617600B2 (en) 2009-04-18 2017-04-11 Genentech, Inc. Methods for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies
WO2011084605A1 (en) * 2009-12-16 2011-07-14 The Trustees Of The University Of Pennsylvania Anti-prostate cancer antibodies and methods of detection and treatment of prostate cancer using the same
RS60612B1 (sr) 2010-03-31 2020-08-31 Boehringer Ingelheim Int Anti-cd40 antitela
HUE065915T2 (hu) 2011-03-11 2024-06-28 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antitestek és alkalmazásaik
CA2831294A1 (en) 2011-03-25 2012-10-04 Baylor Research Institute Compositions and methods to immunize against hepatitis c virus
CN103635488B (zh) 2011-04-29 2016-12-14 埃派斯进有限公司 抗-cd40抗体及其使用方法
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
SG10201707813YA (en) * 2011-10-11 2017-11-29 Medimmune Llc Cd40l-specific tn3-derived scaffolds and methods of use thereof
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP2914627B1 (en) 2012-10-30 2021-04-07 Apexigen, Inc. Anti-cd40 antibodies and methods of use
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
AU2015204503B2 (en) 2014-01-13 2020-07-09 Baylor Research Institute Novel vaccines against HPV and HPV-related diseases
KR102526945B1 (ko) 2014-04-30 2023-04-27 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Cd269에 대한 인간화 항체
EP3552665A3 (en) 2014-08-12 2019-12-18 Alligator Bioscience AB Antibodies
AU2015339128C1 (en) 2014-10-29 2021-12-16 Seagen Inc. Dosage and administration of non-fucosylated anti-CD40 antibodies
AU2015350190B2 (en) * 2014-11-18 2021-08-05 Janssen Pharmaceutica Nv CD47 antibodies, methods, and uses
LT3283527T (lt) 2015-04-13 2021-03-25 Five Prime Therapeutics, Inc. Kompleksinė terapija vėžio gydymui
BR112018001907A2 (pt) * 2015-09-01 2018-09-25 Boehringer Ingelheim Int uso de anticorpos anti-cd40 para o tratamento de nefrite lúpica
EP3307322B1 (en) 2015-09-04 2021-02-17 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
MX2018003905A (es) 2015-09-30 2018-09-06 Janssen Biotech Inc Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso.
WO2017062653A2 (en) * 2015-10-08 2017-04-13 The Board Of Trustees Of The Leland Stanford Junior University Blockade of tim-1 for treating graft-versus-host disease
SI3370768T1 (sl) 2015-11-03 2022-04-29 Janssen Biotech, Inc. Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
EA039944B1 (ru) * 2016-01-27 2022-03-30 Бёрингер Ингельхайм Интернациональ Гмбх Применение антител к cd40 для лечения волчаночного нефрита
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
CN109863170B (zh) 2016-08-12 2024-08-16 詹森生物科技公司 具有增强的激动作用和效应子功能的工程化抗体及其他含Fc结构域分子
SG11201900744SA (en) 2016-08-12 2019-02-27 Janssen Biotech Inc Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
WO2018036852A1 (en) 2016-08-25 2018-03-01 F. Hoffmann-La Roche Ag Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
WO2018071345A1 (en) * 2016-10-11 2018-04-19 Integrated Biotherapeutics, Inc. Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop
KR102595048B1 (ko) * 2016-11-07 2023-10-26 씨젠 인크. 조작된-시스테인 캡의 분포
KR102019033B1 (ko) * 2016-11-11 2019-09-06 다이노나(주) Cd40에 특이적으로 결합하는 항체 및 그의 용도
JP7304287B2 (ja) 2016-12-22 2023-07-06 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 抗pd-l1/pd1治療の不成功後の、抗pd-l1抗体との組み合わせでの抗csf-1r抗体を用いた腫瘍の治療
CA3053358A1 (en) 2017-04-04 2018-10-11 F. Hoffmann-La Roche Ag Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
CN110267989B (zh) 2017-06-01 2023-04-04 江苏恒瑞医药股份有限公司 抗cd40抗体、其抗原结合片段及其医药用途
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
SG11202002903XA (en) 2017-11-01 2020-04-29 Hoffmann La Roche Bispecific 2+1 contorsbodies
KR102813744B1 (ko) * 2017-12-27 2025-05-28 브리스톨-마이어스 스큅 컴퍼니 항-cd40 항체 및 그의 용도
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies
KR102716634B1 (ko) 2018-10-01 2024-10-16 에프. 호프만-라 로슈 아게 항-fap 클론 212를 포함하는 이중특이적 항원 결합 분자
WO2020070035A1 (en) * 2018-10-01 2020-04-09 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules with trivalent binding to cd40
EP3860653A1 (en) 2018-10-05 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and systems for controlling the agonistic properties of antibody variable domains by light
JP2022509156A (ja) 2018-11-30 2022-01-20 江蘇恒瑞医薬股▲ふん▼有限公司 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用
CN112839961B (zh) 2018-11-30 2023-04-04 江苏恒瑞医药股份有限公司 一种cd40抗体药物组合物及其用途
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
WO2020253722A1 (en) * 2019-06-17 2020-12-24 Eucure (Beijing) Biopharma Co., Ltd Anti-cd40 antibodies and uses thereof
US20220370418A1 (en) 2019-09-09 2022-11-24 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
TWI851885B (zh) * 2020-03-30 2024-08-11 大陸商正大天晴藥業集團股份有限公司 結合cd40的抗體及其用途
TW202206100A (zh) 2020-04-27 2022-02-16 美商西健公司 癌症之治療
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
TW202229348A (zh) 2020-09-30 2022-08-01 美商西健公司 使用sea-cd40治療葡萄膜黑色素瘤
EP4240415A1 (en) 2020-11-08 2023-09-13 Seagen Inc. Combination-therapy antibody drug conjugate with immune cell inhibitor
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
EP4347657A1 (en) 2021-05-25 2024-04-10 Seagen Inc. Methods of quantifying anti-cd40 antibodies
CN115403670A (zh) 2021-05-26 2022-11-29 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
US20250009877A1 (en) 2021-07-30 2025-01-09 Seagen Inc. Treatment for cancer
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
EP4507779A1 (en) 2022-04-14 2025-02-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6A (en) * 1836-08-10 Thomas Blanchard Machine for forming end pieces of plank blocks for ships
US5182368A (en) 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
IL84285A (en) 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5985847A (en) 1993-08-26 1999-11-16 The Regents Of The University Of California Devices for administration of naked polynucleotides which encode biologically active peptides
US5597569A (en) 1993-10-25 1997-01-28 Bristol-Myers Squibb Company Bryodin 2 a ribosome-inactivating protein isolated from the plant Bryonia dioica
DE69433820T2 (de) 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
WO1998033810A2 (en) 1997-01-30 1998-08-06 University Of Virginia Patent Foundation Cysteine-depleted peptides recognized by a3-restricted cytotoxic lymphocytes, and uses therefor
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
DK1616579T3 (da) * 1998-05-23 2009-09-14 Univ Leiden Medical Ct CD40 bindende molekyler og CTL peptider til behandling af tumorer
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
CA2402596A1 (en) * 2000-03-16 2001-09-27 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
RU2287574C2 (ru) * 2000-12-14 2006-11-20 Дженентек, Инк. БАКТЕРИЯ Е.coli, ПРОДУЦИРУЮЩАЯ ГЕТЕРОЛОГИЧНЫЙ ПОЛИПЕПТИД, И СПОСОБ ПРОДУЦИРОВАНИЯ ПОЛИПЕПТИДА
WO2004073656A2 (en) * 2003-02-20 2004-09-02 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
US20060003412A1 (en) 2003-12-08 2006-01-05 Xencor, Inc. Protein engineering with analogous contact environments
WO2006017538A2 (en) * 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
CN101223448B (zh) * 2005-05-20 2012-01-18 健泰科生物技术公司 来自自身免疫病受试者的生物学样品的预处理
ATE485057T1 (de) * 2005-05-26 2010-11-15 Seattle Genetics Inc Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung

Similar Documents

Publication Publication Date Title
JP2008541733A5 (OSRAM)
RU2766094C2 (ru) Антитела, нацеленные на антиген созревания в-клеток, и способы их применения
RU2007148932A (ru) Гуманизированные анти-cd40-антитела и способы их применения
CN109071654B (zh) 靶向Fc受体样5的抗体及使用方法
RU2445319C2 (ru) Моноклональные антитела к клаудину-18 для лечения рака
US9758586B2 (en) Chimeric rabbit/human ROR1 antibodies
RU2725819C2 (ru) Антитела, нацеленные на рецептор, связанный с g-белками, и способы их применения
JP2005515963A5 (OSRAM)
JP2006502699A5 (OSRAM)
JP7257971B2 (ja) 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用
JP2025041695A (ja) 抗体および使用方法
CN118201965A (zh) 抗trop-2抗体或其抗原结合片段
TW201904999A (zh) 抗gitr抗體、其抗原結合片段及其醫藥用途
HK40059306A (en) Antibodies targeting b-cell maturation antigen and methods of use
RU2774158C2 (ru) Антитела, направленные против fc-рецептор-подобного белка 5, и способы их применения
HK40058700A (en) Antibodies targeting b-cell maturation antigen and methods of use
HK1243956B (zh) 靶向b-细胞成熟抗原的抗体及其用途